GeneDx is trading at $72.50 (+6.84%) after reporting Q2 revenue of $114.4 million, which exceeded analyst expectations and highlighted strong operational momentum.
- The company saw 32% growth in exome and genome test volume and reported a return to adjusted net income of $0.4 million.
- Management reaffirmed its full-year 2026 revenue guidance of $475 million to $490 million, signaling confidence in sustained growth.